Onconova Therapeutics Inc. (ONTX)

Oncology Corporate Profile

Stock Performance

0.4600
-0.0500

3 Month Stock History Chart

HQ Location

375 Pheasant Run
Newton, PA 18940

Company Description

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells.

Website: http://www.onconova.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
rigosertibmitotic inhibitorMyelodysplastic Syndrome (MDS)III
rigosertib (+ azacitidine)mitotic inhibitorMyelodysplastic Syndrome (MDS)II
briciclib / ON 013105cyclin D1 inhibitorVarious cancer typesI
ON 123300c-MYC activated kinases dual inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.onconova.com

Recent News Headlines

Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination

9/26/2016 12:19 pm

(StreetInsider) Sept 26, 2016 - Pivotal randomized trial in 1st-line MDS patients will assess overall response rate as approval endpoint.

Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting

6/7/2016 07:24 pm

(Onconova Therapeutics) June 6, 2016 - Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data relating to the mechanistic rationale for combining rigosertib with azacitidine at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.

Biocept Introduces Liquid Biopsy Test To Detect RET Fusions In Patients With NSCLC

5/24/2016 11:05 am

(PharmaBiz.com [India]) May 23, 2016 - Biocept, Inc., a leading molecular diagnostics company with liquid biopsy technology for cancer profiling and monitoring, announced the launch of its test to detect RET oncogene fusions from a simple blood draw. Positive identification of patients with the RET gene provides important information in determining therapy options including targeted tyrosine kinase inhibitors.

Baxalta Ending Licensing Agreement for Onconova's Lead Candidate Rigosertib

3/4/2016 06:48 pm

(Genetic Engineering & Biotechnology News) Mar 4, 2016 - Baxalta is ending a 3 1/2-year-old agreement with Onconova Therapeutics to license European commercialization rights to its Phase III lead candidate rigosertib.

Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer

2/22/2016 07:00 am

(Pfizer) Feb 19, 2016 - First-in-class therapy now approved for use in a broader range of women; new indication supported by results of phase 3 PALOMA-3 Trial of IBRANCE in combination with fulvestrant.

Does Radiation Therapy Improve Survival for Women with Ductal Carcinoma in Situ (DCIS)? Yes...and...No.

2/2/2016 12:00 pm

(Brigham and Women’s Hospital) Feb 1, 2016 - Set of risk factors predict which patients with ductal carcinoma in situ (DCIS) will see a survival benefit from radiation therapy after breast cancer surgery.

Palpation for Thyroid Nodules in Cancer Survivors Saves $$

1/21/2016 11:05 am

(Medscape Medical News) Jan 21, 2016 - Thyroid nodules are very common after radiation exposure, and even though most are benign, some professional societies recommend periodic screening with ultrasound for individuals at high risk for thyroid cancer.

The Questions Cancer Survivors Don’t Ask Doctors

9/4/2015 12:01 pm

(US News & World Report) Sep 3, 2015 - Today is an important day for Jane – it's her "first birthday," marking one year since completing cancer treatment.

Genentech Receives FDA Breakthrough Therapy Designation for ACE910

9/4/2015 12:01 pm

(StreetInsider) Sep 4, 2015 - Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to ACE910 (RG6013, RO5534262) for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors.

AstraZeneca Wins U.S. Approval for Longer Use of Blood Thinner

9/4/2015 12:01 pm

(Reuters) Sep 4, 2015 - U.S. regulators have approved a new dose of AstraZeneca's blood thinner Brilinta for longer-term use in patients with a history of heart attacks, boosting prospects for a drug the company thinks will eventually sell $3.5 billion a year.

White House Takes Aim at Medicare and Medicaid Billing Errors

9/4/2015 12:01 pm

(NPR/Shots blog) Sep 3, 2015 - White House budget director Shaun Donovan called for a "more aggressive strategy" to thwart improper government payments to doctors, hospitals and insurance companies in a previously undisclosed letter to Health and Human Services Secretary Sylvia Mathews Burwell earlier this year.

Could Mobile Devices Raise Skin Cancer Risk?

9/4/2015 12:00 pm

(Reuters) Sept 3, 2015 - Devices like tablets, smartphones and laptops can reflect ultraviolet light from the sun and may indirectly increase users' exposure to the cancer-causing wavelengths, according to a new study.

Novartis Receives EU Approval for Farydak(R), the First in Its Class of Anticancer Agents Approved for Patients with Multiple Myeloma

9/4/2015 12:00 pm

(MarketWatch) Sep 4, 2015 - Novartis International receives EU approval for Farydak, the first in its class of anticancer agents approved for patients with multiple myeloma.

AZ' NSCLC Drug Clears First Hurdle to Early Access in the UK

9/4/2015 12:00 pm

(PharmaTimes [UK]) Sep 3, 2015 - AstraZeneca’s non-small cell lung cancer drug AZD9291 has cleared the first stage of a two-step process for being included in the UK’s Early Access to Medicine Scheme.

2015 Palliative Care in Oncology Press Program to Feature New Tools, Insights for the Delivery of High-Quality Palliative Care

9/4/2015 12:00 pm

(ASCO) Sep 3, 2015 - Co-sponsors of the 2015 Palliative Care in Oncology Symposium announced today three abstracts that will be highlighted in the meeting’s official Press Program.

MD Anderson and Cellectis Announce Pre-Clinical and Clinical Alliance in Cancer Immunotherapy

9/4/2015 12:00 pm

(MD Anderson) Sep 3, 2015 - Cellectis, the gene editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors.

Variations in Cell Programs Control Cancer and Normal Stem Cells

9/4/2015 12:00 pm

(Whitehead Institute) Sep 3, 2015 - In the breast, cancer stem cells and normal stem cells can arise from different cell types but tap into distinct yet related stem cell programs, according to Whitehead Institute researchers.

Proposed Medicare Cuts to Radiation Therapy Are Bad Medicine

9/4/2015 12:00 pm

(The Hill blog) Sep 3, 2015 - Cancer is a cruel disease. It is unpredictable and indiscriminate, and it continues to take nearly 600,000 American lives each year.

A Little Known Side Effect with a Huge Impact

9/4/2015 11:05 am

(Fred Hutch) Sep 3, 2015 - First, there was achiness, a pain that never went away.

Chemokine Immune Molecule Inhibits Growth and Spread of Pancreatic Cancer

9/4/2015 11:05 am

(Medical College of Wisconsin) Sep 1, 2015 - Scientists at the Medical College of Wisconsin (MCW) have demonstrated that a chemokine protein (CXCL12), an important molecule of the body's immune system, can suppress metastasis which is the spread of cancer from one part of the body to another.

Genomic Sequencing Shows Benefit for Children with Cancer

9/4/2015 11:05 am

(Medscape Oncology) Sep 3, 2015 - Incorporating genomic sequencing and genetic counseling could benefit children with rare, relapsed, or refractory cancer, according to investigators.

Hach Shows Age Not Always a Barrier to Cancer Therapy

9/4/2015 11:05 am

(VICC) Sep 3, 2015 - Phila Hach recently celebrated her 89th birthday and she has had much to celebrate over the years.

Advaxis and Sorrento Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies

5/19/2015 12:00 pm

(MarketWatch) May 19, 2015 - Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, Inc. to evaluate combinations of Advaxis’s Lm-LLO cancer immunotherapy technology platform.

Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting

4/22/2015 04:24 pm

(Yahoo! Finance) Apr 21, 2015 - Onconova Therapeutics, Inc. today announced the highlighting of data from its lead and other proprietary compounds at the 2015 AACR Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.

Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)

2/3/2015 06:44 pm

(NASDAQ) Feb 3, 2015 - Onconova Therapeutics, Inc. today announced that following discussions regarding the future development of rigosertib with the FDA, the EMA, and several European national regulatory agencies, the Company has solidified its plans for a Phase 3 clinical trial for rigosertib in HR-MDS patients after failure of treatment with HMAs.

Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting

12/8/2014 11:14 pm

(Yahoo! Finance) Dec 7, 2014 - Onconova Therapeutics, Inc. today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.

Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting

12/8/2014 12:41 am

(The Street) Dec 7, 2014 - Onconova Therapeutics, Inc. today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.

Onconova's MDS Study Fails and I Explain What I Got Wrong.

2/20/2014 05:43 pm

(The Street) Feb 20, 2014 - The failure of the rigosertib study in high-risk MDS patients is a setback but not the end for Onconova. The company noted Wednesday that a phase III study of rigosertib in low-risk MDS patients will be started as soon as possible.

Onconova Announces Results From Phase 3 ONTIME Trial of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)

2/20/2014 12:32 pm

(Yahoo! Finance) Feb 19, 2014 - Rigosertib vs. Best Supportive Care did not meet the primary endpoint of statistically significant improvement in median overall survival.

Onconova's MDS Study Fails and I Explain What I Got Wrong.

2/20/2014 11:04 am

(The Street) Feb 20, 2014 - The failure of the rigosertib study in high-risk MDS patients is a setback but not the end for Onconova. The company noted Wednesday that a phase III study of rigosertib in low-risk MDS patients will be started as soon as possible.

Onconova Announces Results From Phase 3 ONTIME Trial of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)

2/20/2014 06:03 am

(Yahoo! Finance) Feb 19, 2014 - Rigosertib vs. Best Supportive Care did not meet the primary endpoint of statistically significant improvement in median overall survival.

Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study

12/18/2013 12:48 pm

(Onconova Therapeutics) Dec 17, 2013 - Onconova Therapeutics, Inc. today announced the discontinuation of the Phase 3 ONTRAC study of intravenous (IV) rigosertib plus gemcitabine in front-line metastatic pancreatic cancer.

Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study

12/18/2013 06:04 am

(Onconova Therapeutics) Dec 17, 2013 - Onconova Therapeutics, Inc. today announced the discontinuation of the Phase 3 ONTRAC study of intravenous (IV) rigosertib plus gemcitabine in front-line metastatic pancreatic cancer.

Onconova Announces Presentation of Positive Data From Clinical Trials of Rigosertib in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting

12/10/2013 12:23 am

(Yahoo! Finance) Dec 9, 2013 – Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced two presentations relating to clinical trials of its most advanced product candidate, rigosertib, at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, December 7-10, 2013.

Onconova Announces Presentation of Positive Data From Clinical Trials of Rigosertib in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting

12/9/2013 06:02 pm

(Yahoo! Finance) Dec 9, 2013 – Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced two presentations relating to clinical trials of its most advanced product candidate, rigosertib, at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, December 7-10, 2013.

‘White Bagging’ of Specialty Drugs Draws Some Ire

12/2/2013 10:03 am

(Pharmacy Practice News) November Issue 2013 - With the growing number of patients using specialty pharmacy medications, hospitals and clinics that are not part of the limited-distribution networks for those drugs face serious financial and operational challenges.